166 related articles for article (PubMed ID: 12120207)
1. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer.
Ding XZ; Tong WG; Adrian TE
Pancreatology; 2001; 1(4):291-9. PubMed ID: 12120207
[TBL] [Abstract][Full Text] [Related]
2. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells.
Ding XZ; Iversen P; Cluck MW; Knezetic JA; Adrian TE
Biochem Biophys Res Commun; 1999 Jul; 261(1):218-23. PubMed ID: 10405349
[TBL] [Abstract][Full Text] [Related]
3. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
Ding XZ; Tong WG; Adrian TE
Anticancer Res; 2000; 20(4):2625-31. PubMed ID: 10953335
[TBL] [Abstract][Full Text] [Related]
4. Lipoxygenase metabolism: roles in tumor progression and survival.
Pidgeon GP; Lysaght J; Krishnamoorthy S; Reynolds JV; O'Byrne K; Nie D; Honn KV
Cancer Metastasis Rev; 2007 Dec; 26(3-4):503-24. PubMed ID: 17943411
[TBL] [Abstract][Full Text] [Related]
5. Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells.
Ding XZ; Kuszynski CA; El-Metwally TH; Adrian TE
Biochem Biophys Res Commun; 1999 Dec; 266(2):392-9. PubMed ID: 10600514
[TBL] [Abstract][Full Text] [Related]
6. Primers on molecular pathways - lipoxygenases: their role as an oncogenic pathway in pancreatic cancer.
Comba A; Pasqualini ME
Pancreatology; 2009; 9(6):724-8. PubMed ID: 20016244
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of 12-LOX and COX-2 reduces the proliferation of human epidermoid carcinoma cells (A431) by modulating the ERK and PI3K-Akt signalling pathways.
Agarwal S; Achari C; Praveen D; Roy KR; Reddy GV; Reddanna P
Exp Dermatol; 2009 Nov; 18(11):939-46. PubMed ID: 19558494
[TBL] [Abstract][Full Text] [Related]
8. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.
Hong SH; Avis I; Vos MD; Martínez A; Treston AM; Mulshine JL
Cancer Res; 1999 May; 59(9):2223-8. PubMed ID: 10232612
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
Ye YN; Wu WK; Shin VY; Bruce IC; Wong BC; Cho CH
Carcinogenesis; 2005 Apr; 26(4):827-34. PubMed ID: 15637091
[TBL] [Abstract][Full Text] [Related]
10. Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model.
Ding X; Zhou X; Zhang H; Qing J; Qiang H; Zhou G
Cancer Chemother Pharmacol; 2012 Jan; 69(1):253-61. PubMed ID: 21713446
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of acyclic triaryl (Z)-olefins possessing a 3,5-di-tert-butyl-4-hydroxyphenyl pharmacophore: dual inhibitors of cyclooxygenases and lipoxygenases.
Moreau A; Rao PN; Knaus EE
Bioorg Med Chem; 2006 Aug; 14(15):5340-50. PubMed ID: 16677817
[TBL] [Abstract][Full Text] [Related]
12. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.
Shappell SB; Olson SJ; Hannah SE; Manning S; Roberts RL; Masumori N; Jisaka M; Boeglin WE; Vader V; Dave DS; Shook MF; Thomas TZ; Funk CD; Brash AR; Matusik RJ
Cancer Res; 2003 May; 63(9):2256-67. PubMed ID: 12727848
[TBL] [Abstract][Full Text] [Related]
13. Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention.
Cathcart MC; Lysaght J; Pidgeon GP
Cancer Metastasis Rev; 2011 Dec; 30(3-4):363-85. PubMed ID: 22134655
[TBL] [Abstract][Full Text] [Related]
14. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors.
Matsuyama M; Yoshimura R; Mitsuhashi M; Hase T; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
Int J Oncol; 2004 Apr; 24(4):821-7. PubMed ID: 15010818
[TBL] [Abstract][Full Text] [Related]
15. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.
Molina MA; Sitja-Arnau M; Lemoine MG; Frazier ML; Sinicrope FA
Cancer Res; 1999 Sep; 59(17):4356-62. PubMed ID: 10485483
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of lipoxygenase inhibitors on murine bladder cancer cell line (MBT-2).
Ikemoto S; Sugimura K; Kuratukuri K; Nakatani T
Anticancer Res; 2004; 24(2B):733-6. PubMed ID: 15161019
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model.
Melstrom LG; Bentrem DJ; Salabat MR; Kennedy TJ; Ding XZ; Strouch M; Rao SM; Witt RC; Ternent CA; Talamonti MS; Bell RH; Adrian TA
Clin Cancer Res; 2008 Oct; 14(20):6525-30. PubMed ID: 18927292
[TBL] [Abstract][Full Text] [Related]
18. New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy.
Pommery N; Taverne T; Telliez A; Goossens L; Charlier C; Pommery J; Goossens JF; Houssin R; Durant F; Hénichart JP
J Med Chem; 2004 Dec; 47(25):6195-206. PubMed ID: 15566290
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs).
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2006 Dec; 14(23):7898-909. PubMed ID: 16904331
[TBL] [Abstract][Full Text] [Related]
20. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade.
Tavolari S; Bonafè M; Marini M; Ferreri C; Bartolini G; Brighenti E; Manara S; Tomasi V; Laufer S; Guarnieri T
Carcinogenesis; 2008 Feb; 29(2):371-80. PubMed ID: 18033773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
